Hawaii Abortion Pill In-Person Rule Fight Paused for FDA Review

May 10, 2021, 2:20 PM

Hawaii-based litigation over a requirement that a drug used to induce an abortion be delivered to a woman in person has been halted, pending the Food and Drug Administration’s reconsideration of the restriction, a federal district court said.

The U.S. District Court for the District of Hawaii granted a motion jointly filed by the government and health-care providers to pause the case in light of an FDA statement that it’s reconsidering a risk evaluation and mitigation strategy for mifepristone, one-half of a two-drug regimen used in medication abortions.

The restriction requires women to get the pill in person from a ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.